CATXNYSEPharmaceutical PreparationsFiscal year ends December 31
Perspective Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$2.19+0.02 (+0.92%)
Close on Oct 19, 2026
- Market cap
- $264.23M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2010 to 2025
Gross margin
–
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2015 | FY2019 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -16.5% | -80.9% | -41.4% | |
| Return on assets | -14.9% | -61.0% | -33.9% | |
| Current ratio | 14.95 | 6.53 | 5.17 | |
| Debt to equity | – | – | 0.01 | |
| Net debt to EBITDA | – | – | 0.26× | |
| Interest coverage | -2168.5× | – | – | |
| Inventory turnover | 11.6× | 8.3× | – | |
| Capex to revenue | 2.9% | 6.1% | – | |
| Diluted shares | 5M | 7M | 74M |
Where the cash went
Fiscal 2020 to 2025, five years combined
Perspective Therapeutics generated $114.97M from operations and spent $68.08M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$114.97M
Used
$68.08M
Capital expenditure$68.08M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-67.4%
×Asset turnover0.16×
×Equity multiplier1.05×
=Return on equity, FY2022-11.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2022 | -67.4% | 0.16× | 1.05× | -11.3% |
| FY2021 | -33.7% | 0.25× | 1.08× | -9.3% |
| FY2020 | -35.6% | 1.07× | 1.35× | -51.4% |
| FY2019 | -70.3% | 0.87× | 1.33× | -80.9% |
| FY2018 | -113.1% | 0.60× | 1.26× | -85.7% |
| FY2017 | -129.4% | 0.31× | 1.12× | -45.6% |
| FY2016 | -98.8% | 0.23× | 1.11× | -25.3% |
| FY2015 | -79.9% | 0.19× | 1.11× | -16.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$103.12M
- Cash generatingOperating cash flow above zero-$82.48M
- Return on assets improvedROA up on the prior year– → -30.2%
- Earnings backed by cashOperating cash flow above net income-$82.48M vs -$103.12M
- Less leverageLong-term debt to assets fell0.5% → 0.6%
- Better liquidityCurrent ratio rose12.68 → 5.17
- No dilutionShare count did not rise64M → 74M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –